Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant TACE for Stage I/II HCC
NCT02109146Phase 3Completed
- Sponsor
- Zhejiang University
- Start
- Mar 2014
- Primary completion
- May 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of epirubicin, oxaliplatin in hepatocellular carcinoma (HCC), sponsored by Zhejiang University. Started Mar 2014; status: completed.
02
Drugs
epirubicinoxaliplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02109146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02109146.